New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma.Results of the ...

Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...